In Vitro activity of ceftolozane-tazobactam against anaerobic organisms identified during the ASPECT-cIAI study

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 666-668

  Armstrong, Eliana S ^a   Farrell, David J ^b   Palchak, Melissa ^a   Steenbergen, Judith N ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE; HEMIN; MEROPENEM; METRONIDAZOLE; PHYTOMENADIONE; TAZOBACTAM; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ABDOMINAL INFECTION; AGAR DILUTION; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BACTEROIDES; BACTEROIDES FRAGILIS; BACTEROIDES STERCORIS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES VULGATUS; BROTH DILUTION; DRUG POTENCY; FUSOBACTERIUM; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PARABACTEROIDES DISTASONIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVOTELLA; PRIORITY JOURNAL; QUALITY CONTROL; ANAEROBIC GROWTH; ANALOGS AND DERIVATIVES; BACTEROIDES INFECTIONS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GRAM POSITIVE BACTERIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; INTRAABDOMINAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; PROCEDURES;

ANAEROBIOSIS; ANTI-BACTERIAL AGENTS; BACTEROIDES; BACTEROIDES FRAGILIS; BACTEROIDES INFECTIONS; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID;

EID: 84957928522     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01964-15     Document Type: Article

References (8)

1. Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. 2014. Antimicrobial activity of ceftolozane-tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-2012). J Antimicrob Chemother 69:2713-2722. http://dx.doi.org/10.1093/jac/dku184.
2. Sader HS, Farrell DJ, Flamm RK, Jones RN. 2014. Ceftolozane-tazobactam activity tested against aerobic Gram-negative organisms isolated from intraabdominal and urinary tract infections in European and United States hospitals (2012). J Infect 69:266-277. http://dx.doi.org/10.1016/j.jinf.2014.04.004.
3. Cubist Pharmaceuticals. 2014. Zerbaxa package insert. Cubist Pharmaceuticals, Lexington, MA.
4. Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C. 2015. Ceftolozane-tazobactam plus metronidazole for complicated intraabdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60:1462-1471. http://dx.doi.org/10.1093/cid/civ097.
5. Clinical and Laboratories Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI M100-S20. Clinical and Laboratories Standards Institute, Wayne, PA.
6. Clinical and Laboratories Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard - 8th ed. CLSI M11-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratories Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Snydman DR, McDermott LA, Jacobus NV. 2014. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother 58:1218-1223. http://dx.doi.org/10.1128/AAC.02253-13.